PT  - JOURNAL ARTICLE
AU  - Lei, Lei
AU  - Qian, Hongbo
AU  - Yang, Xiaofang
AU  - Zhou, Xiaobo
AU  - Zhang, Xingzhe
AU  - Zhang, Dan
AU  - Dai, Tongxin
AU  - Guo, Rui
AU  - Shi, Lin
AU  - Cheng, Yanbin
AU  - Zhang, Baojun
AU  - Hu, Jinsong
AU  - Guo, Yaling
TI  - The phenotypic changes of γδ T cells in COVID-19 patients
AID  - 10.1101/2020.04.05.20046433
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.05.20046433
4099  - http://medrxiv.org/content/early/2020/04/07/2020.04.05.20046433.short
4100  - http://medrxiv.org/content/early/2020/04/07/2020.04.05.20046433.full
AB  - A novel pneumonia-associated respiratory syndrome named coronavirus disease-2019 (COVID-19), which caused by SARS-CoV-2 and broken in Wuhan, China in the end of 2019. Unfortunately, there is no specific antiviral agent or vaccine available to treat SARS-CoV-2 infections. Also, information regarding the immunological characteristics in COVID-19 patients remains limited. Here we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes in γδ T cells. In comparison to HD, the γδ T cells percentage was decreased. γδ T cells are able to immediately respond to SARS-CoV-2 infection and upregulate the activation marker CD25. In addition, the increased expression of CD4 in γδ T cells may serve as a biomarker for the assessment of SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grants from Natural Science Foundation of China (NSFC, Grant No. 81820108017 and 81771673) and a COVID-19 special project from Xi’an Jiaotong University Foundation (xzy032020002).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCorrespondence and requests for all data should be addressed to Baojun Zhang (bj.zhang@mail.xjtu.edu.cn)